

Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G5E064FDD219EN.html>

Date: May 2026

Pages: 138

Price: US\$ 3,660.00 (Single User License)

ID: G5E064FDD219EN

Abstracts

The global Gastroesophageal Junction Adenocarcinoma Therapeutics market size is predicted to grow from US\$ 8652 million in 2025 to US\$ 28080 million in 2032; it is expected to grow at a CAGR of 18.7% from 2026 to 2032.

Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.

The gastroesophageal junction adenocarcinoma therapeutics market is driven by the increasing incidence of this aggressive cancer and the growing demand for effective treatment options. Gastroesophageal junction adenocarcinoma is a type of cancer that affects the junction between the esophagus and the stomach. The rise in risk factors, such as obesity, gastroesophageal reflux disease, and *Helicobacter pylori* infection, contributes to market growth. The development of targeted therapies, such as immune checkpoint inhibitors and HER2-targeted agents, has improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the late diagnosis of the disease, as it is often detected at an advanced stage, and the limited effectiveness of current treatments in advanced cases. Additionally, the high cost of specialized therapies and the need for personalized treatment approaches can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective gastroesophageal junction adenocarcinoma therapeutics.

LPI (LP Information)' newest research report, the "Gastroesophageal Junction

Adenocarcinoma Therapeutics Industry Forecast” looks at past sales and reviews total world Gastroesophageal Junction Adenocarcinoma Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Gastroesophageal Junction Adenocarcinoma Therapeutics sales for 2026 through 2032. With Gastroesophageal Junction Adenocarcinoma Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Gastroesophageal Junction Adenocarcinoma Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Gastroesophageal Junction Adenocarcinoma Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gastroesophageal Junction Adenocarcinoma Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastroesophageal Junction Adenocarcinoma Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastroesophageal Junction Adenocarcinoma Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastroesophageal Junction Adenocarcinoma Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Gastroesophageal Junction Adenocarcinoma Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:

Drug

Surgery

Chemotherapy

Targeted Therapy

Segmentation by Application:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Astellas Pharmaceuticals

AstraZeneca

Bayer

Beigene

Bristol-Myers Squibb

Daichii Sankyo

Elevar Therapeutics

Eli Lilly

FivePrime Therapeutics

Incyte

Macrogenics

Merck Co

Ono Pharmaceuticals

Roche

Taiho Pharmaceuticals

Zai Labs

ZymeWorks

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size (2021-2032)

- 2.1.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)

- 2.1.3 World Current & Future Analysis for Gastroesophageal Junction Adenocarcinoma Therapeutics by Country/Region (2021, 2025 & 2032)

2.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Segment by Type

- 2.2.1 Drug

- 2.2.2 Surgery

- 2.2.3 Chemotherapy

- 2.2.4 Targeted Therapy

- 2.2.5 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type

- 2.2.5.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)

- 2.2.5.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type (2021-2026)

2.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Segment by Application

- 2.3.1 Hospital Pharmacy

- 2.3.2 Retail Pharmacy

- 2.3.3 Online Pharmacy

- 2.3.4 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application

- 2.3.4.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size

CAGR by Application (2021 VS 2025 VS 2032)

2.3.4.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Application (2021-2026)

3 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA THERAPEUTICS MARKET SIZE BY PLAYER

3.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Player

3.1.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue by Player (2021-2026)

3.1.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Player (2021-2026)

3.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA THERAPEUTICS BY REGION

4.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2021-2026)

4.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Annual Revenue by Country/Region (2021-2026)

4.3 Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth (2021-2026)

4.4 APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth (2021-2026)

4.5 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth (2021-2026)

4.6 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2021-2026)

5.2 Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026)

5.3 Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2021-2026)

6.2 APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026)

6.3 APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2021-2026)

7.2 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026)

7.3 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics by Region (2021-2026)

8.2 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026)

8.3 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA THERAPEUTICS MARKET FORECAST

10.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Region (2027-2032)

10.1.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Region (2027-2032)

10.1.2 Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.1.3 APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.1.4 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.1.5 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.2 Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Country (2027-2032)

10.2.1 United States Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.2.2 Canada Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.2.3 Mexico Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.2.4 Brazil Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.3 APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Region (2027-2032)

10.3.1 China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Forecast

10.3.2 Japan Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.3.3 Korea Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.3.4 Southeast Asia Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.3.5 India Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.3.6 Australia Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.4 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Country (2027-2032)

10.4.1 Germany Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.4.2 France Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.4.3 UK Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.4.4 Italy Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.4.5 Russia Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.5 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Region (2027-2032)

10.5.1 Egypt Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.5.2 South Africa Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.5.3 Israel Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.5.4 Turkey Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

10.6 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Type (2027-2032)

10.7 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast by Application (2027-2032)

10.7.1 GCC Countries Market Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast

11 KEY PLAYERS ANALYSIS

11.1 Astellas Pharmaceuticals

11.1.1 Astellas Pharmaceuticals Company Information

11.1.2 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.1.3 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.1.4 Astellas Pharmaceuticals Main Business Overview

11.1.5 Astellas Pharmaceuticals Latest Developments

11.2 AstraZeneca

11.2.1 AstraZeneca Company Information

11.2.2 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.2.3 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 AstraZeneca Main Business Overview

11.2.5 AstraZeneca Latest Developments

11.3 Bayer

11.3.1 Bayer Company Information

11.3.2 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.3.3 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 Bayer Main Business Overview

11.3.5 Bayer Latest Developments

11.4 Beigene

11.4.1 Beigene Company Information

11.4.2 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.4.3 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

- 11.4.4 Beigene Main Business Overview
- 11.4.5 Beigene Latest Developments
- 11.5 Bristol-Myers Squibb
 - 11.5.1 Bristol-Myers Squibb Company Information
 - 11.5.2 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.5.3 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 Bristol-Myers Squibb Main Business Overview
 - 11.5.5 Bristol-Myers Squibb Latest Developments
- 11.6 Daichii Sankyo
 - 11.6.1 Daichii Sankyo Company Information
 - 11.6.2 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.6.3 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Daichii Sankyo Main Business Overview
 - 11.6.5 Daichii Sankyo Latest Developments
- 11.7 Elevar Therapeutics
 - 11.7.1 Elevar Therapeutics Company Information
 - 11.7.2 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.7.3 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Elevar Therapeutics Main Business Overview
 - 11.7.5 Elevar Therapeutics Latest Developments
- 11.8 Eli Lilly
 - 11.8.1 Eli Lilly Company Information
 - 11.8.2 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.8.3 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Eli Lilly Main Business Overview
 - 11.8.5 Eli Lilly Latest Developments
- 11.9 FivePrime Therapeutics
 - 11.9.1 FivePrime Therapeutics Company Information
 - 11.9.2 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.9.3 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma

Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.9.4 FivePrime Therapeutics Main Business Overview

11.9.5 FivePrime Therapeutics Latest Developments

11.10 Incyte

11.10.1 Incyte Company Information

11.10.2 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.10.3 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.10.4 Incyte Main Business Overview

11.10.5 Incyte Latest Developments

11.11 Macrogenics

11.11.1 Macrogenics Company Information

11.11.2 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.11.3 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.11.4 Macrogenics Main Business Overview

11.11.5 Macrogenics Latest Developments

11.12 Merck Co

11.12.1 Merck Co Company Information

11.12.2 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.12.3 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.12.4 Merck Co Main Business Overview

11.12.5 Merck Co Latest Developments

11.13 Ono Pharmaceuticals

11.13.1 Ono Pharmaceuticals Company Information

11.13.2 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

11.13.3 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

11.13.4 Ono Pharmaceuticals Main Business Overview

11.13.5 Ono Pharmaceuticals Latest Developments

11.14 Roche

11.14.1 Roche Company Information

11.14.2 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

- 11.14.3 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
- 11.14.4 Roche Main Business Overview
- 11.14.5 Roche Latest Developments
- 11.15 Taiho Pharmaceuticals
 - 11.15.1 Taiho Pharmaceuticals Company Information
 - 11.15.2 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.15.3 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.15.4 Taiho Pharmaceuticals Main Business Overview
 - 11.15.5 Taiho Pharmaceuticals Latest Developments
- 11.16 Zai Labs
 - 11.16.1 Zai Labs Company Information
 - 11.16.2 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.16.3 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.16.4 Zai Labs Main Business Overview
 - 11.16.5 Zai Labs Latest Developments
- 11.17 ZymeWorks
 - 11.17.1 ZymeWorks Company Information
 - 11.17.2 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered
 - 11.17.3 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 11.17.4 ZymeWorks Main Business Overview
 - 11.17.5 ZymeWorks Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Gastroesophageal Junction Adenocarcinoma Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Drug

Table 4. Major Players of Surgery

Table 5. Major Players of Chemotherapy

Table 6. Major Players of Targeted Therapy

Table 7. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 8. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 9. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type (2021-2026)

Table 10. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 11. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 12. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Application (2021-2026)

Table 13. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue by Player (2021-2026) & (\$ millions)

Table 14. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Player (2021-2026)

Table 15. Gastroesophageal Junction Adenocarcinoma Therapeutics Key Players Head office and Products Offered

Table 16. Gastroesophageal Junction Adenocarcinoma Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 17. New Products and Potential Entrants

Table 18. Mergers & Acquisitions, Expansion

Table 19. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2021-2026) & (\$ millions)

Table 20. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Region (2021-2026)

Table 21. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue

by Country/Region (2021-2026) & (\$ millions)

Table 22. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Country/Region (2021-2026)

Table 23. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2021-2026) & (\$ millions)

Table 24. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Country (2021-2026)

Table 25. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 26. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type (2021-2026)

Table 27. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 28. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Application (2021-2026)

Table 29. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2021-2026) & (\$ millions)

Table 30. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Region (2021-2026)

Table 31. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 32. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 33. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country (2021-2026) & (\$ millions)

Table 34. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Country (2021-2026)

Table 35. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 36. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region (2021-2026) & (\$ millions)

Table 38. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type (2021-2026) & (\$ millions)

Table 39. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application (2021-2026) & (\$ millions)

Table 40. Key Market Drivers & Growth Opportunities of Gastroesophageal Junction Adenocarcinoma Therapeutics

Table 41. Key Market Challenges & Risks of Gastroesophageal Junction Adenocarcinoma Therapeutics

Table 42. Key Industry Trends of Gastroesophageal Junction Adenocarcinoma Therapeutics

Table 43. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 44. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share Forecast by Region (2027-2032)

Table 45. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 46. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 47. Astellas Pharmaceuticals Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 48. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 49. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 50. Astellas Pharmaceuticals Main Business

Table 51. Astellas Pharmaceuticals Latest Developments

Table 52. AstraZeneca Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 53. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 54. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 55. AstraZeneca Main Business

Table 56. AstraZeneca Latest Developments

Table 57. Bayer Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 58. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 59. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 60. Bayer Main Business

Table 61. Bayer Latest Developments

Table 62. Beigene Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 63. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product

Offered

Table 64. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 65. Beigene Main Business

Table 66. Beigene Latest Developments

Table 67. Bristol-Myers Squibb Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 68. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 69. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 70. Bristol-Myers Squibb Main Business

Table 71. Bristol-Myers Squibb Latest Developments

Table 72. Daichii Sankyo Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 73. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 74. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 75. Daichii Sankyo Main Business

Table 76. Daichii Sankyo Latest Developments

Table 77. Elevar Therapeutics Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 78. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 79. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 80. Elevar Therapeutics Main Business

Table 81. Elevar Therapeutics Latest Developments

Table 82. Eli Lilly Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 83. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 84. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 85. Eli Lilly Main Business

Table 86. Eli Lilly Latest Developments

Table 87. FivePrime Therapeutics Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 88. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 89. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 90. FivePrime Therapeutics Main Business

Table 91. FivePrime Therapeutics Latest Developments

Table 92. Incyte Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 93. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 94. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 95. Incyte Main Business

Table 96. Incyte Latest Developments

Table 97. Macrogenics Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 98. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 99. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 100. Macrogenics Main Business

Table 101. Macrogenics Latest Developments

Table 102. Merck Co Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 103. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 104. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 105. Merck Co Main Business

Table 106. Merck Co Latest Developments

Table 107. Ono Pharmaceuticals Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 108. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 109. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 110. Ono Pharmaceuticals Main Business

Table 111. Ono Pharmaceuticals Latest Developments

Table 112. Roche Details, Company Type, Gastroesophageal Junction

Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 113. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 114. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 115. Roche Main Business

Table 116. Roche Latest Developments

Table 117. Taiho Pharmaceuticals Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 118. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 119. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 120. Taiho Pharmaceuticals Main Business

Table 121. Taiho Pharmaceuticals Latest Developments

Table 122. Zai Labs Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 123. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 124. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 125. Zai Labs Main Business

Table 126. Zai Labs Latest Developments

Table 127. ZymeWorks Details, Company Type, Gastroesophageal Junction Adenocarcinoma Therapeutics Area Served and Its Competitors

Table 128. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offered

Table 129. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 130. ZymeWorks Main Business

Table 131. ZymeWorks Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Gastroesophageal Junction Adenocarcinoma Therapeutics Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Gastroesophageal Junction Adenocarcinoma Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Gastroesophageal Junction Adenocarcinoma Therapeutics Sales Market Share by Country/Region (2025)

Figure 8. Gastroesophageal Junction Adenocarcinoma Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type in 2025

Figure 10. Gastroesophageal Junction Adenocarcinoma Therapeutics in Hospital Pharmacy

Figure 11. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Hospital Pharmacy (2021-2026) & (\$ millions)

Figure 12. Gastroesophageal Junction Adenocarcinoma Therapeutics in Retail Pharmacy

Figure 13. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Retail Pharmacy (2021-2026) & (\$ millions)

Figure 14. Gastroesophageal Junction Adenocarcinoma Therapeutics in Online Pharmacy

Figure 15. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Online Pharmacy (2021-2026) & (\$ millions)

Figure 16. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Application in 2025

Figure 17. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share by Player in 2025

Figure 18. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Region (2021-2026)

Figure 19. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2021-2026 (\$ millions)

Figure 20. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2021-2026 (\$ millions)

Figure 21. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2021-2026 (\$ millions)

Figure 23. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Value Market Share by Country in 2025

Figure 24. United States Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Region in 2025

Figure 29. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type (2021-2026)

Figure 30. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Application (2021-2026)

Figure 31. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Country in 2025

Figure 38. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type (2021-2026)

Figure 39. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market

Size Market Share by Application (2021-2026)

Figure 40. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 42. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 54. APAC Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 55. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 57. United States Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 58. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 61. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 62. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 63. Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 65. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 66. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 67. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 68. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 69. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 70. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 71. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 74. Israel Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size 2027-2032 (\$ millions)

Figure 76. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Gastroesophageal Junction Adenocarcinoma Therapeutics

Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G5E064FDD219EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5E064FDD219EN.html>